Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesUrologyPremera Bluecross BPH Policy Update | OpenPayer
    Ask Trek AI about this page
    ModifiedPremera BluecrossPolicy 2.01.544

    Transurethral Water Vapor Thermal Therapy and Transurethral Waterjet Ablation for Benign Prostatic Hyperplasia

    Customize your policy alerts

    Sign up for Premera Bluecross Policy 2.01.544 alerts

    Get alerted when Policy 2.01.544 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity and coverage criteria for transurethral water vapor thermal therapy and transurethral waterjet ablation (Aquablation) for benign prostatic hyperplasia with lower urinary tract obstruction. It guides providers submitting these services for coverage.

    Policy Summary
    PayerPremera Bluecross
    PolicyTransurethral Water Vapor Thermal Therapy and Transurethral Waterjet Ablation for Benign Prostatic Hyperplasia
    Policy CodePolicy 2.01.544
    Change TypeModified
    Effective DateOct 1, 2026
    Last ReviewSep 8, 2026
    Next Review DateN/A
    Key ActionBefore either procedure, document failure or inability to tolerate maximally titrated medical therapy for at least 3 months.
    SourceLink
    POLICY UPDATE CHANGES

    The 2026 annual review added refractory urinary retention secondary to BPH requiring an indwelling catheter or intermittent self-catheterization as a medical necessity pathway for both Rezum and Aquablation.

    The prostate-volume criterion for transurethral waterjet ablation was expanded from greater than 30 mL and less than or equal to 80 mL to less than or equal to 150 mL.

    The policy clarified that medical necessity is met solely when refractory urinary retention requiring catheterization is present or when the IPSS/AUASS is at least 12 and additional criteria are satisfied.

    The policy title was updated to Transurethral Water Vapor Thermal Therapy and Transurethral Waterjet Ablation for Benign Prostatic Hyperplasia.

    CPT code 52597 was added effective January 1, 2026.

    IPSS/AUASS ≥12Symptom-score threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    >30 to ≤80 mLWater vapor prostate volume
    >30 to ≤150 mLWaterjet prostate volume
    ≥3 monthsMedical therapy trial
    InvestigationalRepeat ablation procedures

    Medical Necessity and Coverage Criteria

    Transurethral water vapor thermal therapy (Rezum)

    Transurethral water vapor thermal therapy is medically necessary when all of the following conditions are met.

    Rezum medical necessity criteria

    • Retention or symptom-score pathway

      • Refractory urinary retention secondary to BPH requiring an indwelling catheter or intermittent self-catheterization.
      • Symptom score: IPSS/AUASS of 12 or higher.≥12
    • Medical therapy failure or intolerance: Failure or inability to tolerate maximally titrated medical therapy with an alpha-1 adrenergic antagonist, 5-alpha reductase inhibitor, or combination medication therapy over a trial period of no less than 3 months.≥3 months
    • Prostate volume: Imaging shows prostate gland volume greater than 30 mL and less than or equal to 80 mL.>30 mL and ≤80 mL
    • No exclusion conditions: The individual does not have an actively treated urinary tract infection, actively treated prostatitis, or known or suspected prostate cancer.

      All listed exclusion conditions must be absent.

    Transurethral waterjet ablation (Aquablation)

    Transurethral waterjet ablation is medically necessary when all of the following conditions are met.

    Aquablation medical necessity criteria

    • Retention or symptom-score pathway

      • Refractory urinary retention secondary to BPH requiring an indwelling catheter or intermittent self-catheterization.
      • Symptom score: IPSS/AUASS of 12 or higher.≥12
    • Medical therapy failure or intolerance: Failure or inability to tolerate maximally titrated medical therapy with an alpha-1 adrenergic antagonist, 5-alpha reductase inhibitor, or combination medication therapy over a trial period of no less than 3 months.≥3 months

    Medical necessity pathways for Rezum and Aquablation

    For both Rezum and Aquablation, medical necessity is established through one of the following pathways. The symptom-score pathway requires the additional criteria listed below.

    Medical necessity pathway

    • One of the following pathways

      • Refractory urinary retention pathway: Refractory urinary retention secondary to BPH requiring an indwelling catheter or intermittent self-catheterization.

        This pathway was added for both procedures in the 2026 annual review.

      • Symptom-score pathway

        • Medical therapy criterion: Failure or inability to tolerate maximally titrated medical therapy with an alpha-1 adrenergic antagonist, 5-alpha reductase inhibitor, or combination medication therapy over a trial period of no less than 3 months.≥3 months

    Transurethral waterjet ablation prostate-volume criterion

    For LUTS/BPH, transurethral waterjet ablation requires imaging documentation of the applicable prostate-volume range.

    Waterjet ablation prostate-volume criterion: The individual has lower urinary tract symptoms or obstruction due to benign prostatic hyperplasia, and imaging shows a prostate gland volume greater than 30 mL and less than or equal to 150 mL.>30 mL and ≤150 mL

    The policy revised the upper limit from 80 mL to 150 mL. AUA guidance identifies 30–80 cc as the recommended range and permits offering waterjet treatment at 80–150 cc based on expert opinion.

    Transurethral water vapor thermal therapy (Rezum) and transurethral waterjet ablation (Aquablation) are considered investigational when used to treat any condition other than benign prostatic hyperplasia (BPH).

    Repeat transurethral water vapor thermal therapy treatments are considered investigational.

    Repeat transurethral waterjet ablation treatments are considered investigational.

    Transurethral water vapor thermal therapy (Rezum) is not medically necessary for BPH when the applicable criteria are not met, including the required symptom or retention pathway, failure or intolerance of maximally titrated medical therapy for no less than 3 months, prostate volume of >30 mL and ≤80 mL, and absence of the listed exclusion conditions.

    Transurethral waterjet ablation (Aquablation) is not medically necessary for BPH when the applicable criteria are not met, including the required symptom or retention pathway, failure or intolerance of maximally titrated medical therapy for no less than 3 months, prostate volume of >30 mL and ≤150 mL, and absence of the listed exclusion conditions.

    Coding and Threshold Reference

    CPTCPT
    0421TTransurethral waterjet ablation of prostate, including control of post-operative bleeding, including ultrasound guidance, complete (vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy are included when performed) (code termed effective 01/01/26)
    52597Transurethral robotic-assisted waterjet resection of prostate, including intraoperative planning, ultrasound guidance, control of postoperative bleeding, complete, including vasectomy, meatotomy, cystourethoscopy, urethral calibration and/or dilation, and internal urethrotomy, when performed (new code effective 01/01/26)
    HCPCSHCPCS
    C2596Probe, image guided, robotic, waterjet ablation
    Historical procedure and HCPCS codesmixed
    0421TCPT code referenced in policy history; later terminated and removed effective January 1, 2026.
    C2596HCPCS code added in the 2021 policy update.
    2026 coding updateCPT
    52597New CPT code added effective January 1, 2026.
    0421TTerminated CPT code removed effective January 1, 2026.
    FDA product codesmixed
    KNSFDA product code for the Rezum System.
    PZPFDA product code for the Aquabeam System.
    IPSS/AUASS symptom-score threshold
    Eligibility thresholdIPSS/AUASS of 12 or higher
    Applies toThe symptom-score pathway for transurethral water vapor thermal therapy
    DocumentationThe medical record must document the IPSS/AUASS score when this pathway is used
    Rezum prostate-volume criterion
    Eligible prostate volumeGreater than 30 mL and less than or equal to 80 mL
    Measurement method

    Documentation and Submission Requirements

    Step Therapy

    Three-Month Medical Therapy Trial

    Before either procedure, document failure or inability to tolerate maximally titrated medical therapy over a trial period of no less than 3 months.

    • Therapy may include α1-adrenergic antagonists, 5α-reductase inhibitors, or combination medication therapy.
    • Document the medications, titration, duration, response, and any intolerance.
    Documentation Required

    General Medical Records Required

    Submit medical records showing that the medical-necessity criteria are met, identify whether Rezum or Aquablation is requested, and include relevant office documentation.

    • Office visit notes containing the relevant history and physical.
    • Documentation supporting the applicable obstruction, symptom, therapy, imaging, and exclusion criteria.

    Condition Overview

    Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate that may cause bladder outlet obstruction and lower urinary tract symptoms, including frequency, urgency, weak urinary stream, straining, and nocturia. Transurethral water vapor thermal therapy uses radiofrequency-generated water vapor to ablate obstructing prostate tissue, while Aquablation uses a pressurized fluid jet to cut prostate tissue. Both are minimally invasive alternatives to transurethral resection of the prostate for appropriately selected patients.

    Terms and Technologies

    International Prostate Symptom Score (IPSS)
    DefinitionA standardized, validated measure used to assess the severity of lower urinary tract symptoms
    Additional assessmentThe questionnaire assesses lower urinary tract symptoms and quality of life
    UseIt can be used to assess disease severity, response to therapy, and treatment selection
    American Urological Association Symptom Score (AUASS)
    DefinitionThe symptom questionnaire corresponding to the American Urological Association Symptom Index and IPSS
    Symptoms assessedIncomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nighttime urination
    Policy Summary
    PayerPremera Bluecross
    PolicyTransurethral Water Vapor Thermal Therapy and Transurethral Waterjet Ablation for Benign Prostatic Hyperplasia
    Policy CodePolicy 2.01.544
    Change TypeModified
    Effective DateOct 1, 2026
    Last ReviewSep 8, 2026
    Next Review DateN/A
    Key ActionBefore either procedure, document failure or inability to tolerate maximally titrated medical therapy for at least 3 months.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaCoding and Threshold ReferenceDocumentation and Submission RequirementsCondition OverviewTerms and Technologies
  1. Prostate volume: Imaging shows prostate gland volume greater than 30 mL and less than or equal to 150 mL.>30 mL and ≤150 mL
  2. No exclusion conditions: The individual does not have an actively treated urinary tract infection, actively treated prostatitis, or known or suspected prostate cancer.

    All listed exclusion conditions must be absent.

  3. Applicable prostate-volume criterion: Imaging documents an eligible prostate volume: greater than 30 mL and no greater than 80 mL for Rezum, or greater than 30 mL and no greater than 150 mL for Aquablation.Rezum: >30 to ≤80 mL; Aquablation: >30 to ≤150 mL
  4. No exclusion conditions: The individual does not have an actively treated urinary tract infection, actively treated prostatitis, or known or suspected prostate cancer.
  5. Imaging must show the prostate gland volume
    ProcedureTransurethral water vapor thermal therapy (Rezum)
    Aquablation prostate-volume criterion
    Eligible prostate volumeGreater than 30 mL and less than or equal to 150 mL
    Measurement methodImaging must show the prostate gland volume
    ProcedureTransurethral waterjet ablation (Aquablation)
    Medical therapy trial
    Minimum durationNo less than 3 months
    Treatment requirementFailure or inability to tolerate maximally titrated medical therapy
    Acceptable therapyAn alpha-1 adrenergic antagonist, 5-alpha reductase inhibitor, or combination medication therapy
    IPSS/AUASS symptom severity categories
    Mild symptoms1-7
    Moderate symptoms8-19
    Severe symptoms20-35
    Clarified IPSS/AUASS threshold
    Clarified thresholdIPSS/AUASS of 12 or higher
    Medical necessity pathwayThe symptom-score pathway requires the threshold plus the additional applicable medical necessity criteria
    Alternative pathwayRefractory urinary retention secondary to BPH requiring an indwelling catheter or intermittent self-catheterization
    Revised waterjet prostate-volume limit
    Revised upper limitLess than or equal to 150 mL
    Prior upper limitThe criterion was previously less than or equal to 80 mL
    ProcedureTransurethral waterjet ablation
    AUA water vapor thermal therapy range
    AUA-recommended range30-80 cc
    TreatmentWater vapor thermal therapy
    Clinical indicationLower urinary tract symptoms attributed to benign prostatic hyperplasia
    AUA waterjet treatment ranges
    Recommended range30-80 g
    Expert-opinion extensionWaterjet treatment may be offered at 80-150 cc
    Clinical indicationLower urinary tract symptoms attributed to benign prostatic hyperplasia
    Documentation Required

    Obstruction and Symptom Severity

    Document moderate-to-severe lower urinary tract obstruction due to BPH and establish one qualifying severity pathway: refractory urinary retention requiring catheterization, or an IPSS/AUASS of 12 or higher.

    • Refractory retention must be secondary to BPH and require an indwelling catheter or intermittent self-catheterization.
    • Alternatively, document IPSS or AUASS ≥ 12 with supporting clinical history.
    Step Therapy

    Prior Medical Therapy

    Document failure or inability to tolerate the specified maximally titrated medical therapy before requesting either procedure.

    • α1-adrenergic antagonists, 5α-reductase inhibitors, or combination medication therapy.
    • The trial must last no less than 3 months.
    Documentation Required

    Prostate-Volume Imaging

    Submit imaging documenting a prostate gland volume greater than 30 mL and within the applicable procedure-specific upper limit.

    • Rezum: >30 mL and ≤80 mL.
    • Aquablation: >30 mL and ≤150 mL.
    Denial Risk

    Disqualifying Concurrent Condition

    Document that none of the disqualifying concurrent conditions is present or being actively treated.

    • Urinary tract infection being actively treated.
    • Prostatitis being actively treated.
    • Known or suspected prostate cancer.
    Documentation Required

    Refractory Urinary Retention Documentation

    For the retention pathway, document refractory urinary retention secondary to BPH and the required catheterization.

    • Indwelling catheter or intermittent self-catheterization is required.
    • Link the retention to benign prostatic hypertrophy (BPH).
    Documentation Required

    Symptom-Score Documentation

    For the symptom-score pathway, submit the IPSS or AUASS demonstrating a score of 12 or higher and supporting documentation of moderate-to-severe lower urinary tract obstruction due to BPH.

    • Document the score and date of assessment.
    • Include the relevant history and physical findings.
    Documentation Required

    Aquablation Prostate-Volume Documentation

    For Aquablation, submit imaging supporting a prostate volume greater than 30 mL and less than or equal to 150 mL.

    • The revised upper limit is 150 mL.
    • Volumes outside the applicable range create a noncoverage risk.
    Denial Risk

    Criteria Not Met

    Treatment is not medically necessary when the applicable medical-necessity criteria are not satisfied.

    • This applies to Rezum and Aquablation requests for BPH.
    • Ensure the qualifying pathway and all additional criteria are documented before submission.
    Denial Risk

    Non-BPH Indication

    Treatment with transurethral water vapor thermal therapy or transurethral waterjet ablation for a condition other than benign prostatic hyperplasia is investigational.

    • Document that the requested treatment is for lower urinary tract obstruction due to BPH.
    Denial Risk

    Repeat Treatment

    Repeat treatments using transurethral water vapor thermal therapy or transurethral waterjet ablation are considered investigational.

    • Document whether the requested procedure is an initial treatment.
    Denial Risk

    Disqualifying Concurrent Condition

    Do not submit either procedure as medically necessary when an active infection, active prostatitis, or known or suspected prostate cancer is present.

    • Urinary tract infection being actively treated.
    • Prostatitis being actively treated.
    • Known or suspected prostate cancer.
    Denial Risk

    Medical Necessity Pathway Not Met

    Medical necessity is not established when neither qualifying pathway is documented.

    • Refractory urinary retention secondary to BPH requiring an indwelling catheter or intermittent self-catheterization; or
    • IPSS/AUASS of 12 or higher, with all additional criteria met.
    Denial Risk

    Aquablation Volume Criterion Not Met

    Aquablation is not medically necessary when the prostate-volume requirement is not satisfied.

    • Required volume: >30 mL and ≤150 mL.
    • Submit imaging that clearly supports the applicable range.
    ScoringThe score ranges from 0 to 35 and is categorized as mild, moderate, or severe
    Transurethral water vapor thermal therapy
    DefinitionA minimally invasive procedure using heated, radiofrequency-generated water vapor to ablate prostate tissue obstructing the urethra
    Energy sourceRadiofrequency-generated water vapor thermal energy
    Policy terminologyRezum is an example of transurethral water vapor thermal therapy
    Transurethral waterjet ablation
    DefinitionA minimally invasive procedure that cuts prostate tissue using a pressurized jet of fluid delivered to the prostatic urethra
    Treatment methodPressurized fluid cuts and removes obstructing prostate tissue
    Policy terminologyAquablation is an example of transurethral waterjet ablation
    IPSS/AUASS
    MeaningInternational Prostate Symptom Score or American Urological Association Symptom Score
    Policy threshold12 or higher
    Use in coverage criteriaThe threshold applies to the symptom-score pathway when the additional medical necessity criteria are also met
    Rezum System
    ProductA transurethral convective radiofrequency water-vapor therapy system
    Intended useTo relieve symptoms and obstruction and reduce prostate tissue associated with benign prostatic hyperplasia
    FDA-indicated prostate volume30 cm³ to less than or equal to 150 cm³ under the expanded indication
    Aquabeam System
    ProductA waterjet system
    Intended useResection and removal of prostate tissue in males with lower urinary tract symptoms due to benign prostatic hyperplasia
    FDA clearanceCleared through the de novo classification process and later received 510(k) clearance for the same indications